Institute of Bacteriology, University of Strasbourg, Strasbourg, France.
Antimicrob Agents Chemother. 2012 May;56(5):2485-92. doi: 10.1128/AAC.05745-11. Epub 2012 Feb 27.
Staphylococcus aureus is a frequent cause of acute endophthalmitis, and infection with this virulent bacterium is often associated with a poor visual outcome. In this study, we investigated the bactericidal efficacy and the safety of intravitreal daptomycin (DAP), a lipopeptide antibiotic with broad-spectrum activity against Gram-positive bacteria, compared with those of intravitreal vancomycin (VAN) in a methicillin-resistant S. aureus endophthalmitis rabbit model. The pharmacokinetics and pharmacodynamics of daptomycin in the infected eyes were also studied. Rabbits were randomly divided into three treatment groups (n = 8) and one untreated group (n = 4), to compare the effect of single intravitreal injections of 0.2 mg and 1 mg of daptomycin (DAP 0.2 and DAP 1 groups, respectively) with that of 1 mg of intravitreal vancomycin (VAN 1 group). Vitreal aspirates were regularly collected and grading of ocular inflammation was regularly performed until euthanasia on day 7. In the DAP 0.2 group, 62.5% of the eyes were sterilized and the mean bacterial count presented a reduction of 1 log unit. In the DAP 1 and VAN 1 groups, the infection was eradicated (100% and 87.5% of eyes sterilized, respectively), with a 4-log-unit reduction of the mean bacterial count. The bactericidal efficacy in the DAP 1 group was not inferior to that in the VAN 1 group and was superior to that of the other regimens in limiting the ocular inflammation and preserving the architecture of the ocular structures (P < 0.05). The elimination half-life (t(1/2β)) of daptomycin was independent of the administered dose (38.8 ± 16.5 h and 40.9 ± 6.7 h, respectively, for the DAP 0.2 and DAP 1 groups) and was significantly longer than the t(1/2β) of vancomycin (20.5 ± 2.0 h for the VAN 1 group) (P < 0.05). This antibiotic could therefore be considered for the treatment of intraocular infections caused by Gram-positive bacteria.
金黄色葡萄球菌是急性眼内炎的常见病因,感染这种毒力强的细菌通常与视觉预后不良有关。在这项研究中,我们研究了达托霉素(DAP)的杀菌效果和安全性,达托霉素是一种具有广谱抗革兰氏阳性菌活性的脂肽抗生素,与万古霉素(VAN)比较,在耐甲氧西林金黄色葡萄球菌眼内炎兔模型中的作用。还研究了达托霉素在受感染眼中的药代动力学和药效动力学。兔子被随机分为三组(n = 8)和一组未治疗组(n = 4),以比较 0.2 毫克和 1 毫克单剂量玻璃体内注射达托霉素(DAP 0.2 和 DAP 1 组)与 1 毫克玻璃体内万古霉素(VAN 1 组)的效果。定期收集玻璃体内吸出物,并定期进行眼部炎症分级,直到第 7 天安乐死。在 DAP 0.2 组中,62.5%的眼睛被消毒,平均细菌计数减少了 1 个对数单位。在 DAP 1 和 VAN 1 组中,感染被消除(分别有 100%和 87.5%的眼睛被消毒),平均细菌计数减少了 4 个对数单位。DAP 1 组的杀菌效果不劣于 VAN 1 组,在限制眼内炎症和保持眼结构结构方面优于其他方案(P <0.05)。达托霉素的消除半衰期(t(1/2β))与给予的剂量无关(DAP 0.2 和 DAP 1 组分别为 38.8 ± 16.5 h 和 40.9 ± 6.7 h),明显长于万古霉素的 t(1/2β)(VAN 1 组为 20.5 ± 2.0 h)(P <0.05)。因此,这种抗生素可被认为是治疗由革兰氏阳性菌引起的眼内感染的一种选择。